Literature DB >> 26194319

The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?

Dorothy M Jones-Davis1, Neil Buckholtz2.   

Abstract

In the growing landscape of biomedical public-private-partnerships, particularly for Alzheimer's disease, the question is posed as to their value. What impacts do public-private-partnerships have on clinical and basic science research in Alzheimer's disease? The authors answer the question using the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a test case and example. ADNI is an exemplar of how public-private-partnerships can make an impact not only on clinical and basic science research and practice (including clinical trials), but also of how similar partnerships using ADNI as an example, can be designed to create a maximal impact within their fields.
Copyright © 2015 The Alzheimer's Association. All rights reserved.

Entities:  

Keywords:  ADNI; Alzheimer's disease; Consortia; FNIH; Foundation for the National Institutes of Health; NIA; National Institute on Aging; Public private partnerships

Mesh:

Year:  2015        PMID: 26194319      PMCID: PMC4513361          DOI: 10.1016/j.jalz.2015.05.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  16 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

4.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

5.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Authors:  Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2011-12-02       Impact factor: 44.182

6.  Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

7.  The essential nature of sharing in science.

Authors:  Beth A Fischer; Michael J Zigmond
Journal:  Sci Eng Ethics       Date:  2010-11-25       Impact factor: 3.525

8.  Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community.

Authors:  Heather M Snyder; Lisa J Bain; Robert Egge; Maria C Carrillo
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

9.  Consortium sandbox: building and sharing resources.

Authors:  Mark D Lim
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

Review 10.  Worldwide Alzheimer's disease neuroimaging initiative.

Authors:  Maria C Carrillo; Lisa J Bain; Giovanni B Frisoni; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2012-07       Impact factor: 21.566

View more
  7 in total

Review 1.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

2.  Imaging Biomarker Development for Lower Back Pain Using Machine Learning: How Image Analysis Can Help Back Pain.

Authors:  Bilwaj Gaonkar; Kirstin Cook; Bryan Yoo; Banafsheh Salehi; Luke Macyszyn
Journal:  Methods Mol Biol       Date:  2022

3.  Deep phenotyping for precision medicine in Parkinson's disease.

Authors:  Ann-Kathrin Schalkamp; Nabila Rahman; Jimena Monzón-Sandoval; Cynthia Sandor
Journal:  Dis Model Mech       Date:  2022-06-01       Impact factor: 5.732

Review 4.  Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Authors:  Remco L A de Vrueh; Daan J A Crommelin
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

5.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

6.  Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.

Authors:  Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz
Journal:  Neurology       Date:  2017-10-25       Impact factor: 9.910

7.  Accelerating drug development for Alzheimer's disease through the use of data standards.

Authors:  Jon Neville; Steve Kopko; Klaus Romero; Brian Corrigan; Bob Stafford; Elizabeth LeRoy; Steve Broadbent; Martin Cisneroz; Ethan Wilson; Eric Reiman; Hugo Vanderstichele; Stephen P Arnerić; Diane Stephenson
Journal:  Alzheimers Dement (N Y)       Date:  2017-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.